ADCendo

ADCendo is a biotechnology company dedicated to developing novel anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) targeting new antigens, and by concentrating on cancer-related targets, we are elevating the ADC approach to new levels. These targets are specialized internalizing targets that achieve superior selectivity through highly prioritized cancer expression. ADCs are a class of highly potent biopharmaceutical drugs, consisting of antibodies chemically linked to biologically active drugs or cytotoxic compounds.